0001562180-19-005523.txt : 20191114 0001562180-19-005523.hdr.sgml : 20191114 20191114184608 ACCESSION NUMBER: 0001562180-19-005523 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191113 FILED AS OF DATE: 20191114 DATE AS OF CHANGE: 20191114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scheer David CENTRAL INDEX KEY: 0001378585 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33095 FILM NUMBER: 191221991 MAIL ADDRESS: STREET 1: ACHILLION PHARMACEUTICALS STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACHILLION PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070336 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 203-624-7000 MAIL ADDRESS: STREET 1: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2019-11-13 false 0001070336 ACHILLION PHARMACEUTICALS INC ACHN 0001378585 Scheer David C/O ACHILLION PHARMACEUTICALS, INC. 1777 SENTRY PARKWAY W, BLDG 14, STE 200 BLUE BELL PA 19422 true false false false Common Stock 2019-11-13 4 M false 20000.00 3.28 A 40000.00 D Common Stock 2019-11-13 4 S false 10485.00 6.3135 D 29515.00 D Common Stock 63249.00 I See footnote Stock Option (Right to Buy) 3.28 2019-11-13 4 M false 20000.00 0.00 D 2019-12-18 Common Stock 20000.00 0.00 D Consists of shares held by Scheer Investment Holdings III, LLC. Mr Scheer is the Managing Member of Scheer Investment Holdings III, LLC. and as such may be deemed to have shared voting and investment power with respect to the shares held by Scheer Investment Holdings III, LLC. Mr. Scheer disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. This option was granted on December 18, 2009 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter. /s/ Keri Lantz, attorney-in-fact 2019-11-14